Vectors for the treatment of autoimmune disease.
Gene therapy has been applied in a variety of experimental models of autoimmunity with some success. In this article, we outline recent developments in gene therapy vectors, discuss advantages and disadvantages of each, and highlight their recent applications in autoimmune models. We also consider progress in vector targeting and components for regulating transgene expression, which will both improve gene therapy safety and empower gene therapy to fullfil its potential as a therapeutic modality. In conclusion, we consider candidate vectors that satisfy requirements for application in the principal therapeutic strategies in which gene therapy will be applied to autoimmune conditions.
1Bone & Joint Research Unit, Barts & The London, Queen Mary's Medical School, University of London, London, UK.
D J
DJ
Gould
P
P
Favorov
D001327:Autoimmune Diseases / Q000628:therapy*; D002985:Clinical Protocols; D004247:DNA / Q000008:administration & dosage; D000229:Dependovirus / Q000235:genetics; D005786:Gene Expression Regulation; D018390:Gene Targeting; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics*; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D012449:Safety; D018139:Simplexvirus / Q000235:genetics
D004247:DNA